

## Justification Document for the Selection of a CoRAP Substance

Group Name: Phenyl amino anthraquinones

EC	CAS	Substance public name
216-475-4	1594-08-7	1-hydroxy-4-[[4- [(methylsulphonyl)oxy]phenyl]amino]anthraquinone
267-636-0	67905-17-3	N-[4-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1- anthryl)amino]phenyl]acetamide

Authority: BE CA

**Date:** 19/03/2019

#### **Cover Note**

This document has been prepared by the evaluating Member State given in the CoRAP update.

1	IDENTITY OF THE SUBSTANCES WITHIN THE GROUP	3
1.1	Other identifiers of the substances within the group	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	5
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	6
<b>3.1</b> 3. 3. 3.	Classification 1.1 Harmonised Classification in Annex VI of the CLP 1.2 Self classification 1.3 Proposal for Harmonised Classification in Annex VI of the CLP	<b>6</b> 6 6
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	7
4.1	Tonnage and registration status	7
4.2	Overview of uses	8
4.2 5. CO	Overview of uses JUSTIFICATION FOR THE SELECTION OF THE CANDIDAT RAP SUBSTANCE OR GROUP	8 E 10
4.2 5. CO 5.1.	Overview of uses JUSTIFICATION FOR THE SELECTION OF THE CANDIDAT RAP SUBSTANCE OR GROUP	8 E 10 10
4.2 5. CO 5.1. 5.2. beir	Overview of uses JUSTIFICATION FOR THE SELECTION OF THE CANDIDAT RAP SUBSTANCE OR GROUP Legal basis for the proposal Selection criteria met (why the substance or group qualifies for ng in CoRAP)	8 E 10 10
4.2 5. CO 5.1. 5.2. beir 5.3	Overview of uses  JUSTIFICATION FOR THE SELECTION OF THE CANDIDAT RAP SUBSTANCE OR GROUP  Legal basis for the proposal  Selection criteria met (why the substance or group qualifies for ng in CoRAP)  Initial grounds for concern to be clarified under Substance Evaluatio	8 E 10 10 10 n 10
4.2 5. 5.1. 5.2. beir 5.3 5.4 the	Overview of uses  JUSTIFICATION FOR THE SELECTION OF THE CANDIDAT RAP SUBSTANCE OR GROUP  Legal basis for the proposal Selection criteria met (why the substance or group qualifies for ng in CoRAP) Initial grounds for concern to be clarified under Substance Evaluatio Indication of information that may need to be requested to clarifyfy concern	8 E 10 10 10 20 10

## **1 IDENTITY OF THE SUBSTANCES WITHIN THE GROUP**

## **1.1** Other identifiers of the substances within the group

EC name (public)	IUPAC name (public)	Inde x num ber in Anne x VI of the CLP Regu latio n	Molec ular formul a	Molec ular weight or molec ular weight range	Synonyms
1-hydroxy-4-[[4- [(methylsulphon yl)oxy]phenyl]a mino]anthraquin one	4-[(4-hydroxy- 9,10-dioxo- 9,10- dihydroanthrac en-1- yl)amino]pheny l methanesulfona te	NA	C21H15N O6S	409.4	9,10- Anthracenedi one, 1- hydroxy-4- 4- (methylsulfon yl)oxy phenyl amino – 9,10- Anthracenedi one, 1- hydroxy-4- [[4- [(methylsulfo nyl) oxy]phenyl]a mino]- 9,10- Anthracenedi one, 1- hydroxy-4- [[4- [(methylsulfo nyl)oxy]phen yl]amino]- 4-[(4- hydroxy- 9,10-dioxo- 9,10- dihydroanthra cen-1- yl)amino]phe

#### JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE

					nyl methanesulfo nate
N-[4-[9,10- dihydro-4- hydroxy-9,10- dioxo-1- anthryl)amino)]p henyl]acetamide	N-{4-[(4- hydroxy-9,10- dioxo-9,10- dihydroanthrac en-1- yl)amino]pheny l}acetamide	NA	C <sub>22</sub> H <sub>16</sub> N <sub>2</sub> O <sub>4</sub>	372.4	Acetamide, N- 4- (9,10- dihydro-4- hydroxy- 9,10-dioxo-1- anthracenyl)a mino phenyl - Acetamide, N-[4-[(9,10- dihydro-4- hydroxy- 9,10-dioxo-1- anthracenyl)a mino]phenyl] - Kenawax Blue X3RP Solvent Blue
					122

## **Type of substances** 🛛 Mono-constituent 🗌 Multi-constituent 🗌 UVCB

#### Structural formulas:

EC 216-475-4:



EC 267-636-0:



#### 2 **OVERVIEW OF OTHER PROCESSES / EU LEGISLATION**

## Table: Completed or ongoing processes

other processes	RMOA	REAC	CH pro	cess	Authorisa	tion	Restriction	h C&L	proce unde other legis	ess r r EU lation	previo legisla	us tion	Stockholm convention	other processes EU legislation
EC entries		ССН	TPE	SEV	candidate list	Annex XIV	Annex XVII	Annex VI (CLP)	PPP	BPR	NONS	RAR	POPs	
216-475-4	/	/	/	/	/	/	/	/	/	/	/	/	/	Manual screening
267-636-0	/	/	/	/	/	/	/	/	/	/	/	/	/	Manual screening

## **3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)**

## **3.1 Classification**

## 3.1.1 Harmonised Classification in Annex VI of the CLP

NA

## 3.1.2 Self classification

• In the registration:

EC Nr	Self-classification					
	Hazard class category code	Hazard statement code				
216-475-4	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317: May cause an allergic skin reaction H400: Very toxic to aquatic life H410: Very toxic to aquatic life with long lasting effects				
267-636-0	Eye Irrit. 2 Aquatic Acute 1	H319: Causes serious eye irritation H400: Very toxic to aquatic life				

• The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Both substances are not classified in the C&L inventory by several notifiers.

# 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

NA

## 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES<sup>1</sup>

## 4.1 Tonnage and registration status

#### Table: Tonnage and registration status<sup>1</sup>

EC 216-475-4

From ECHA dissemination site *				
$\boxtimes$ Full registration(s) (Art. 10)		$\Box$ Intermediate registration(s) (Art. 17 and/or 18)		
Tonnage band (as per dissemination site)				
🗆 1 – 10 tpa	⊠ 10	) – 100 tpa	🗆 100 – 1000 tpa	
🗆 1000 – 10,000 tpa	□ 10,000 - 100,000 tpa		□ 100,000 - 1,000,000 tpa	
□ 1,000,000 - 10,000,000 tpa	□ 10	),000,000 – 100,000,000 tpa	□ > 100,000,000 tpa	
□ <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa) □ Confidential				

#### EC 267-636-0

From ECHA dissemination site *				
$\boxtimes$ Full registration(s) (Art. 10)		$\Box$ Intermediate registration(s) (Art. 17 and/or 18)		
Tonnage band (as per dissemination site)				
🗆 1 – 10 tpa	□ 10	) – 100 tpa	🖂 100 – 1000 tpa	
🗆 1000 – 10,000 tpa	🗆 10,000 - 100,000 tpa		□ 100,000 - 1,000,000 tpa	
□ 1,000,000 - 10,000,000 tpa	□ 10	),000,000 – 100,000,000 tpa	□ > 100,000,000 tpa	
□ <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa) □ Confidential				

\*the total tonnage band has been calculated by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11):

https://echa.europa.eu/documents/10162/22308542/manual\_dissemination\_en.pdf/7e0b8 7c2-2681-4380-8389-cd655569d9f0

<sup>&</sup>lt;sup>1</sup> Dissemination website consulted on 19 July 2018.

## 4.2 Overview of uses

#### Table: Uses (in three parts)

### Part 1:

Substance: EC 216-475-4							
	$\boxtimes$	$\boxtimes$	$\boxtimes$	$\boxtimes$	🛛 Article	Closed	
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system	
		use	use	use			
Substance: EC 267-636-0							
		$\boxtimes$			Article	Closed	
Manufacture	Formulation	Industrial use	Professional use	Consumer use	service life	system	

#### Part 2: Substance1: EC 216-475-4

	Use(s)	Technical function
Uses as intermediate		
Formulation	Industrial formulation of solid preparations containing colorant (including plastics) Use as laboratory reagent Formulation into mixture	
Uses at industrial sites	Textile industrial use-Dyiing Use in laboratory Industrial use of colorant preparations resulting in inclusion into a matrix (including plastics) Use at industrial site leading to inclusion into/onto article	
Uses by professional workers	Treatment of articles by dipping and pouring Textile dyes and impregnating products	
Consumer Uses	Polymer preparations and compounds Colorants and colorants additives	
Article service life	Fabrics, textiles and apparel (outdoor and indoor)	

#### JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE

#### Substance2: 267-636-0

	Use(s)	Technical function
Uses as intermediate	Industrial use as intermediate	
Formulation	/	
Uses at industrial sites	Industrial use in ink and toners Dyestuff application Industrual use of laboratory chemicals Industrial use in colouring of wax products Chemical synthesis Industrial use in colouring of polymer products	
Uses by professional workers	/	
Consumer Uses	/	
Article service life	/	

## 5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE OR GROUP

## 5.1. Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)
- □ Article 45(5) (Member State priority)
- 5.2. Selection criteria met (why the substance or group qualifies for being in CoRAP)
- $\Box$  Fulfils criteria as CMR/ Suspected CMR
- $\hfill \Box$  Fulfils criteria as Sensitiser/ Suspected sensitiser
- $\hfill \square$  Fulfils criteria as potential endocrine disrupter
- Sulfils criteria as PBT/vPvB / Suspected PBT/vPvB
- $\Box$  Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
- $\boxtimes$  Fulfils exposure criteria
- $\Box$  Fulfils MS's (national) priorities

## 5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns							
CMR	Suspected CMR <sup>1</sup> $\Box$ C $\Box$ M $\Box$ R	Potential endocrine disruptor					
	□ Suspected Sensitiser <sup>2</sup>						
PBT/vPvB	Suspected PBT/vPvB <sup>1</sup>	□ Other (please specify):					
Exposure/risk based concerns							
□ Wide dispersive use	Consumer use	Exposure of sensitive populations					
$\Box$ Exposure of environment	$\Box$ Exposure of workers	□ Cumulative exposure					
☐ High RCR	High (aggregated) tonnage	Other (please specify below)					
In the framework of a PBT assessment the grouping of the 2 substances is acceptable as both compounds consist of an anthraquinone core with a phenylamino side chain. The only difference between the two compounds is a different hydrophilic functionality on the phenyl side chain. It is possible that the two parent substances show a somewhat different ecotoxicological profile, but key physico-chemical properties will be similar and once transformation or metabolisation takes place identical degradation products are expected. Therefore, grouping of the two substances seems appropriate.							

For most endpoints QSAR estimations are given but their reliability remains questionable and degradation products (whose identities are currently unknown) may be very relevant regarding PBT assessment.

#### Physico-chemical properties.

It is observed that values of key physico-chemical properties are experimentally not exactly determined (water solubility, vapour pressure, log  $K_{ow}$ , log  $K_{oa}$ , log  $K_{oc}$ ).

For many endpoints QSAR estimations are presented but it is not clear whether these predictions are reliable enough, certainly when basic phys-chem properties are combined like for log  $K_{ow}$ , log  $K_{oa}$  predictions.

#### PBT-assessment:

Definitive information for persistence (simulation studies / half-lives) is not available for both substances. For 1-hydroxy-4-[[4-

[(methylsulphonyl)oxy]phenyl]amino]anthraquinone one study (equivalent to OECD 303 A) suggests ready biodegradability while according to another study (DIN 38'49-H-41-1) no biodegradation at all is observed. For N-[4-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1anthryl)amino]phenyl]acetamide experimental biodegradation studies are not available. Predictions with EpiSuite indicate that depending on the environmental compartment both substances could meet the P and vP-criterion. It is also observed that both substances contain a nitrogen bridge in their chemical structure and the stability of this nitrogen bridge under field conditions is expected to be highly relevant and should be further examined.

Experimental studies on bioaccumulation are not available, nor for aquatic organisms, nor for terrestrial organisms and mammals. In absence of this kind of studies the current screening can only refer to screening B-criteria. In relation to bioaccumulation the log K<sub>ow</sub> and log K<sub>oa</sub>-values are important metrics. These values are not experimentally measured. In the registration dossier following log K<sub>ow</sub> values are reported: for N-[4-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1-anthryl)amino]phenyl]acetamide 4.8 and for 1-hydroxy-4-[[4-[(methylsulphonyl)oxy]phenyl]amino]anthraquinone = 2.49. The log K<sub>oa</sub> values are also not experimentally measured for these two substances; EpiSuite predicts very high values, i.e. around 20. Based on this, there is serious concern that these substances are bioaccumulative for air-breathers and mammals.

In the registration dossier for N-[4-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1anthryl)amino]phenyl]acetamide all ecotoxicity studies are waived. For 1-hydroxy-4-[[4-[(methylsulphonyl)oxy]phenyl]amino]anthraquinone some experimental ecotoxicity studies are available. The most relevant study is a test on freshwater algae that resulted in an NOEC-value of 0.001 mg/L. Although the relevance of algae studies can be questioned, this result indicates that the T-criterion is fulfilled for 1-hydroxy-4-[[4-[(methylsulphonyl)oxy]phenyl]amino]anthraquinone. Based on a read-across argumentation, N-[4-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1anthryl)amino]phenyl]acetamide also potentially meets the T-criterion for the environment.

Therefore, in view of the fact that these substances potentially meet the P/vP criteria, the B/vB criteria (for air-breathers), and the T criterion further analysis of these properties seems appropriate.

<sup>&</sup>lt;sup>2</sup> <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant selfclassification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

Taking into account wide dispersive use (pigment) and the environmental exposure of both substances, the potential risk for human health and environment cannot be excluded. Therefore, BE CA concluded that the concern regarding persistency and bioaccumulation should be addressed under substance evaluation procedure.

## 5.4 Indication of information that may need to be requested to clarifyfy the concern

$oxedsymbol{\boxtimes}$ Information on toxicological properties	Information on physico-chemical properties		
$oxedsymbol{\boxtimes}$ Information on fate and behaviour	$\Box$ Information on exposure		
□ Information on ecotoxicological properties	$\Box$ Information on uses		
$\Box$ Information on ED potential	Other (provide further details below)		
The biodegradation potential will first be further analysed. If the P-character is confirmed, experimental testing on bioaccumulation could be envisaged (potentially via toxicokinetics study).			

## 5.5 Potential follow-up and link to risk management

□ Harmonised C&L	□ Restriction	☑ Authorisation	Other (provide further details)	
In case that the concerns for persistency and bioaccumulation are confirmed, then an identification of both substances as SVHC according to article 57(d) and/or (e) of REACH would be a potential follow-up action in order to improve RMMs for these substances.				